Researchers at the National Eye Institute have developed a new cytokine therapy that delivers functional interleukin 34 (IL-34) to the retina for treating ocular inflammatory diseases – such as uveitis and degenerative retinal diseases. Intraocular delivery of IL-34 protein or IL-34 gene expression system can effectively prevent retinal inflammation. Thus, it may be a promising strategy to produce long-lasting effects in suppressing abnormal retinal inflammation and preventing photoreceptor death.
Researchers at the National Eye Institute (NEI) have discovered a novel therapeutic strategy of using one or more selective estrogen-receptor modulators (SERMs), which may include the FDA-approved drug, Tamoxifen, for treating retinal degenerative diseases, like retinitis pigmentosa (RP) and age-related degeneration (AMD). SERMs exert their specific protection on photoreceptor degeneration likely by inhibiting microglial activation.
Researchers at the National Cancer Institute (NCI) RNA Biology Laboratory have developed nanoparticles that can deliver an agent (i.e., therapeutic or imaging) and release the agent upon targeted photoactivation allowing for controlled temporal and localized release of the agent.
The National Eye Institute (NEI) seek research co-development or licensees for advancing AAV8/9-based therapies for X-linked forms of retinitis pigmentosa (XLRP) caused by mutations in RPGR (retinitis pigmentosa GTPase regulator) or RP2 (retinitis pigmentosa 2) gene.
The National Eye Institute (NEI) and National Institute of Arthritis and Muscoskeletal and Skin Diseases (NIAMS) seeks licensing and/or co-development of a method of producing human retinal pigment epithelial (RPE) cells from human induced pluripotent stem cells (iPSCs).
Scientists at the National Eye Institute (NEI) have developed a technology for a 3D bioprinting process. Through the process, an artificial blood retinal barrier (BRB) is constructed that may be used as a graft to potentially replace BRB tissues that are lost or damaged in many ocular disorders. The printed tissue structures might be therapeutically useful for grafts or as model systems to test function and physiological responses to drugs or other variables introduced into the system.